Current study intended to prepare and evaluate phospholipid-based, mixed micelles (MMs) to improve the ocular delivery of posaconazole (POS), a broad-spectrum antifungal drug. For this, MMs based on egg phosphatidylcholine (EPC), as the main component, in combination with various bile salts (sodium cholate (NaC), sodium deoxycholate (NaDC), sodium taurocholate (NaTC)) or non-ionic surfactants (Pluronic® F-127, Pluronic® F-68, Tween 80, Labrasol® ALF, and d-a-tocopheryl polyethylene glycol 1000 succinate (TPGS)) were prepared. Particle size, polydispersity index, zeta potential and entrapment efficiency were evaluated to optimize the composition and preparation method of the MMs. Finally, morphology, stability, in vitro release pattern, and in vitro antifungal activity of the optimized formulation were investigated. Among the prepared MMs, vesicles composed of EPC: TPGS with a molar ratio of 70:30, prepared by the thin-film hydration method, showed more appropriate features. Among the prepared MMs, vesicles composed of EPC: TPGS with a molar ratio of 70:30 showed more appropriate features, including an entrapment efficiency (EE) greater than 80%, spherical shape morphology, an average particle size of about 58 nm, desirable stability over a month, slow-release without a noticeable initial burst, and a significantly higher in vitro antifungal activity in comparison with the drug suspension. Therefore, this formulation was selected as the optimal MMs and could be considered as a promising carrier for topical ocular delivery of POS.
RammohanRSuneethaVSenS, et al.Fungal infections of the eye. Curr Clin Micro Rpt2020; 7: 39–50.
2.
KakkarSKaruppayilSMRautJS, et al.Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole. Int J Pharm2015; 495: 276–289.
3.
TanureMAGCohenEJSudeshS, et al.Spectrum of fungal keratitis at wills eye hospital, Philadelphia, Pennsylvania. Cornea2000; 19: 307–312.
4.
SantanaACSGVNadvornyDDa Rocha PassosTD, et al.Influence of cyclodextrin on posaconazole stability, release and activity: improve the utility of the drug. J Drug Deliv Sci Technol2019; 53: 101153.
5.
MorrisMI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. AJHP2009; 66: 225–236.
6.
OmranSMTaghizadeh-ArmakiMZarrinfarH, et al.In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. J Infect Chemother2019; 25: 157–160.
7.
NabiliMShokohiTMoazeniM, et al.High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue?J Med Microbiol2016; 65: 468–475.
8.
ArastehfarADaneshniaFZomorodianK, et al.Low level of antifungal resistance in Iranian isolates of Candida glabrata recovered from blood samples in a multicenter study from 2015 to 2018 and potential prognostic values of genotyping and sequencing of PDR1. Antimicrob Agents Chemother2019; 63: e02503–e02518.
9.
MohammedNRejinoldNSMangalathillamS, et al.Fluconazole loaded chitin nanogels as a topical ocular drug delivery agent for corneal fungal infections. J Biomed Nanotech2013; 9: 1521–1531.
10.
Reimondez-TroitiñoSCsabaNAlonsoMJ, et al.Nanotherapies for the treatment of ocular diseases. Eur J Pharm Biopharm2015; 95: 279–293.
11.
VaishyaRDKhuranaVPatelS, et al.Controlled ocular drug delivery with nanomicelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol2014; 6: 422–437.
12.
PiazziniVLanducciEUrruM, et al.Enhanced dissolution, permeation and oral bioavailability of aripiprazole mixed micelles: in vitro and in vivo evaluation. Int J Pharm2020; 583: 119361.
13.
KumarPKumarRSinghB, et al.Biocompatible phospholipid-based mixed micelles for tamoxifen delivery: promising evidences from in - vitro anticancer activity and dermatokinetic studies. AAPS PharmSciTech2017; 18: 2037–2044.
14.
BegSKazmiIAfzalO, et al.Implications of phospholipid-based nanomixed micelles of olmesartan medoxomil with enhanced lymphatic drug targeting ability and systemic bioavailability. J Drug Deliv Sci Technol2021; 62: 102273.
15.
DurgunMEKahramanEHacıoğluM, et al.Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies. Drug Deliv Transl Res2021: 1–14.
16.
DurgunMEMesutBHacıoğluM, et al.Optimization of the micellar-based in situ gelling systems posaconazole with quality by design (qbd) approach and characterization by in vitro studies. Pharmaceutics2022; 14: 526.
17.
KaurIPSmithaR. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm2002; 28: 353–369.
18.
DrescherSVan HoogevestP. The phospholipid research center: current research in phospholipids and their use in drug delivery. Pharmaceutics2020; 12: 1235.
19.
WitikaBAMakoniPAMatafwaliSK, et al.Biocompatibility of biomaterials for nanoencapsulation: current approaches. Nanomaterials2020; 10: 1649.
20.
HaeriASadeghianSRabbaniS, et al.Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. Int J Pharm2013; 455: 320–330.
21.
HaeriASadeghianSRabbaniS, et al.Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis. Int J Pharm2011; 414: 16–27.
22.
KhanK. The concept of dissolution efficiency. J Pharm Pharmacol1975; 27: 48–49.
23.
LattiPRamanarayananSPrashantGM. Antifungal efficacy of spice extracts against candida albicans: an in vitro study. Indian J Community Med2019; 44: S77–S80.
24.
DanaeiMDehghankholdMAtaeiS, et al.Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics2018; 10: 57.
25.
SyedADeviVK. Transdermal delivery of azathioprine by solid lipid nanoparticles: in-vitro and ex-vivo studies. Int J Pharm Sci Res2019; 10: 586.
26.
RuppCSteckelHMullerBW. Solubilization of poorly water-soluble drugs by mixed micelles based on hydrogenated phosphatidylcholine. Int J Pharm2010; 395: 272–280.
27.
GuoQCaiJLiP, et al.Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability. DDDT2016; 10: 3789–3798.
28.
SadeghiMSAlaviSHaeriA, et al.Tacrolimus phospholipid based nanomicelles as a potential local delivery system for corneal neovascularization therapy. IPA2018; 1: 198–207.
29.
Parac-Vogt TatjanaNKimpeKLaurentS, et al.Gadolinium DTPA-monoamide complexes incorporated into mixed micelles as possible MRI contrast agents. Eur J Inorg Chem2004; 2004: 3538–3543.
30.
FaustinoCSerafimCRijoP, et al.Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents. Expert Opin Drug Deliv2016; 13: 1133–1148.
31.
LiYZhangTLiuQ, et al.Mixed micelles loaded with the 5-benzylidenethiazolidine-2, 4-dione derivative SKLB023 for efficient treatment of non-alcoholic steatohepatitis. IJN2019; 14: 3943–3953.
32.
GaridelPJurgenL. Mixed vesicles and mixed micelles: formation, thermodynamic stability, and pharmaceutical aspects. In: GregoriadisG (ed). Liposome Preparation and Related Techniques. 3rd ed.New York, NY: Informa Healthcare, 2007, pp. 209–235.
33.
HammadMAMüllerBW. Solubility and stability of tetrazepam in mixed micelles. Eur J Pharm Sci1998; 7: 49–55.
34.
MaestreAGuardadoPMoyáML. Thermodynamic study of bile salts micellization. J Chem Eng Data2014; 59: 433–438.
35.
PavlovićNGoločorbin-KonSÐanićM, et al.Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol2018; 9: 1283.
36.
LenherrGCsabaNThwalaNL, et al.Nanocapsular Formulation of Active Pharmaceutical Ingredients. Santiago, CA: Universidade de Santiago de Compostela Sanofi SA, 2017.
37.
NaikSChouguleMPadhiB, et al.Development of novel lyophilized mixed micelle amphotericin B formulation for treatment of systemic fungal infection. CDD2005; 2: 177–184.
38.
NagataMYotsuyanagiTIkedaK. Solubilization of vitamin K1 by bile salts and phosphatidylcholine-bile salts mixed micelles. J Pharm Pharmacol1988; 40: 85–88.
39.
RosoffMSerajuddinATM. Solubilization of diazepam in bile salts and in sodium cholate-lecithin-water phases. Int J Pharm1980; 6: 137–146.
40.
De SmidtJHGritMCrommelinDJA. Dissolution kinetics of griseofulvin in mixed micellar solutions. J Pharm Sci1994; 83: 1209–1212.
41.
Alkan-OnyukselHRamakrishnanSChaiHB, et al.A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm Res1994; 11: 206–212.
42.
AlaviSMahjoobMAHaeriA, et al.Multivesicular liposomal depot system for sustained delivery of risperidone: development, characterization, and toxicity assessment. Drug Dev Ind Pharm2021: 1–12.
43.
KaurIPGargASinglaAK, et al.Vesicular systems in ocular drug delivery: an overview. Int J Pharm2004; 269: 1–14.
44.
JiaoJ. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev2008; 60: 1663–1673.
45.
DurgunMEGüngörSÖzsoyY. Micelles: promising ocular drug carriers for anterior and posterior segment diseases. J Ocul Pharmacol Ther2020; 36: 323–341.
46.
MuLFengSS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res2003; 20: 1864–1872.
47.
FengSSZhaoLZhangZ, et al.Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h in vivo. Chem Eng Sci2007; 62: 6641–6648.
48.
StoneNRBicanicTSalimR, et al.Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs2016; 76: 485–500.
49.
SolimanGM. Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges. Int J Pharm2017; 523: 15–32.
50.
ZhangLPornpattananangkuDHuCM, et al.Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem2010; 17: 585–594.
51.
GaoWHuCMFangRH, et al.Liposome-like nanostructures for drug delivery. J Mater Chem B2013; 1: 6569–6585.
